A Phase 1 interventional study of Inhaled placebo + oral placebo and Inhaled alprazolam 0.5 mg in Abuse Liability of Staccato Alprazolam, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.
The Phase 1 clinical study compared the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo in 14 subjects with a history of sedative abuse. Subjects who met the inclusion/exclusion criteria received 2 mg of oral alprazolam and matching placebo over 2 sessions. Those who demonstrated greater liking for alprazolam versus placebo were eligible to participate in the study.
Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
Drug: Inhaled placebo + oral placebo · Drug: Inhaled alprazolam 0.5 mg · Drug: Inhaled alprazolam 1 mg · Drug: Inhaled alprazolam 2 mg · Drug: Oral alprazolam 1 mg · Drug: Oral alprazolam 2 mg · Drug: Oral alprazolam 4 m · Drug: Oral alprazolam 2 mg qualifying session · Drug: Oral placebo qualifying session
Inhaled Staccato placebo + oral placebo
Inhaled Staccato alprazolam 0.5 mg + oral placebo
Inhaled Staccato alprazolam 1 mg + oral placebo
Inhaled Staccato alprazolam 2 mg + oral placebo
Oral alprazolam 1 mg + Inhaled placebo
Oral alprazolam 2 mg + Inhaled placebo
Oral alprazolam 4 mg + Inhaled placebo
Qualifying session (2 mg oral alprazolam)
Qualifying control session (oral placebo)
Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again"
The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, "Rate the degree to which you would like to take the drug again", with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much
Time frame: End of day for each of the 7 crossover treatments
EDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect"
The within patient rank (1-7) of End of Day question number 2 (of primary interest), "Rate your overall liking of the drug effect", response options range from -4 to +4: * 4=Dislike very much * 3=Dislike quite a bit * 2=Dislike somewhat * 1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT * 1=Like, but not very much * 2=Like somewhat * 3=Like quite a bit * 4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: End of day for each of the 7 crossover treatments
EDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street".
EDQ question number 6 (of primary interest)," Estimate the amount of money you think the drug you took today would be worth on the street".
Time frame: End of day for each of the 7 crossover treatments
EDQ Question Number 1, "Rate the Overall Strength of the Drug Effect"
The within patient rank (1-7) of End of Day question number 1, "Rate the overall strength of the drug effect", response options range from 0-4: 0=No drug effect at all 1. Possible mild effect, but not sure 2. Definite mild effect 3. Moderate strong drug effect 4. Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: End of day for each of the 7 crossover treatments
EDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?"
EDQ question number 7," What would you be willing to pay for today's drug?"
Time frame: End of day for each of the 7 crossover treatments
Maximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours)
The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4: "No drug effect at all"=0, "Possible mild effect, but not sure"=1, "Definite mild effect"=2, "Moderate strong drug effect"=3, "Very strong drug effect"=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: DEQ was assessed at the 10 time points (predose through 9 hours)
Maximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours)
The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4: "Dislike very much"=-4, "Dislike quite a bit"=-3, "Dislike somewhat"=-2, "Dislike, but not very much"=-1, "NEUTRAL OR NO EFFECT"=0, "Like, but not very much"=1, "Like somewhat"=2, "Like quite a bit"=3, "Like very much"=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: DEQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness
The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point. The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 5) Maximum of Speech
The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation
The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal
The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
Observer Rated Questionnaire 8) Maximum of Drug Strength
The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
Time frame: ORQ was assessed at the 10 time points (predose through 9 hours)
| Milestone | All Subjects Entering |
|---|---|
| Started | 31 |
| Completed | 15 |
| Not completed | 16 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Inconsistent data reporting | 13 |
| Milestone | All Subjects Entering |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: 14th subject completed trial | 1 |
The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, "Rate the degree to which you would like to take the drug again", with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much
| units on a scale | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" | 0 ± 0.349 | 1.714 ± 0.349 | 2.143 ± 0.349 | 2.286 ± 0.349 | 1.00 ± 0.349 | 1.714 ± 0.349 | 2.214 ± 0.349 |
The within patient rank (1-7) of End of Day question number 2 (of primary interest), "Rate your overall liking of the drug effect", response options range from -4 to +4: * 4=Dislike very much * 3=Dislike quite a bit * 2=Dislike somewhat * 1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT * 1=Like, but not very much * 2=Like somewhat * 3=Like quite a bit * 4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| EDQ Question Number 2 "Rate Your Overall Liking of the Drug Effect" | 1.679 ± 0.349 | 4.214 ± 0.349 | 4.429 ± 0.349 | 4.607 ± 0.349 | 2.571 ± 0.349 | 4.857 ± 0.349 | 5.643 ± 0.349 |
EDQ question number 6 (of primary interest)," Estimate the amount of money you think the drug you took today would be worth on the street".
| Dollars ($) | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| EDQ Question Number 6 " Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street". | 1.750 ± 0.402 | 3.571 ± 0.402 | 7.071 ± 0.402 | 8.714 ± 0.402 | 2.857 ± 0.402 | 4.286 ± 0.402 | 8.571 ± 0.402 |
The within patient rank (1-7) of End of Day question number 1, "Rate the overall strength of the drug effect", response options range from 0-4: 0=No drug effect at all 1. Possible mild effect, but not sure 2. Definite mild effect 3. Moderate strong drug effect 4. Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| EDQ Question Number 1, "Rate the Overall Strength of the Drug Effect" | 1.429 ± 0.317 | 3.536 ± 0.317 | 4.821 ± 0.317 | 5.429 ± 0.317 | 2.893 ± 0.317 | 4.143 ± 0.317 | 5.750 ± 0.317 |
EDQ question number 7," What would you be willing to pay for today's drug?"
| Dollars ($) | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| EDQ Question Number 7,"What Would You be Willing to Pay for Today's Drug?" | 1.607 ± 0.387 | 3.821 ± 0.387 | 4.571 ± 0.387 | 5.179 ± 0.387 | 2.964 ± 0.387 | 4.107 ± 0.387 | 5.750 ± 0.387 |
The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4: "No drug effect at all"=0, "Possible mild effect, but not sure"=1, "Definite mild effect"=2, "Moderate strong drug effect"=3, "Very strong drug effect"=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Maximum of DEQ Question 1 "Rate the Strength of the Drug Effect" (at the 10 Time Points, Predose Through 9 Hours) | 1.571 ± 0.340 | 3.143 ± 0.340 | 4.714 ± 0.340 | 5.536 ± 0.340 | 3.036 ± 0.340 | 4.250 ± 0.340 | 5.750 ± 0.340 |
The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4: "Dislike very much"=-4, "Dislike quite a bit"=-3, "Dislike somewhat"=-2, "Dislike, but not very much"=-1, "NEUTRAL OR NO EFFECT"=0, "Like, but not very much"=1, "Like somewhat"=2, "Like quite a bit"=3, "Like very much"=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Maximum of DEQ Question 2 "Rate Your Liking of the Drug Effect" at the 10 Time Points (Predose Through 9 Hours) | 1.607 ± 0.343 | 3.500 ± 0.343 | 4.536 ± 0.343 | 5.536 ± 0.343 | 2.893 ± 0.343 | 4.250 ± 0.343 | 5.679 ± 0.343 |
The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point. The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness | 2.250 ± 0.313 | 3.679 ± 0.313 | 4.607 ± 0.313 | 4.714 ± 0.313 | 3.929 ± 0.313 | 4.000 ± 0.313 | 4.821 ± 0.313 |
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor | 2.464 ± 0.287 | 2.964 ± 0.287 | 4.643 ± 0.287 | 6.357 ± 0.287 | 2.821 ± 0.287 | 3.571 ± 0.287 | 5.179 ± 0.287 |
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| units on a scale | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor | 2.536 ± 0.282 | 3.036 ± 0.282 | 4.607 ± 0.282 | 6.393 ± 0.282 | 2.714 ± 0.282 | 3.786 ± 0.282 | 4.929 ± 0.282 |
The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture | 2.750 ± 0.337 | 2.893 ± 0.337 | 3.964 ± 0.337 | 6.250 ± 0.337 | 2.929 ± 0.337 | 2.929 ± 0.337 | 2.929 ± 0.337 |
The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 5) Maximum of Speech | 2.214 ± 0.284 | 2.893 ± 0.284 | 4.786 ± 0.284 | 6.393 ± 0.284 | 3.071 ± 0.284 | 3.071 ± 0.284 | 5.357 ± 0.284 |
The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation | 1.929 ± 0.282 | 2.821 ± 0.282 | 4.893 ± 0.282 | 6.429 ± 0.282 | 3.393 ± 0.282 | 3.107 ± 0.282 | 5.429 ± 0.282 |
The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal | 3.964 ± 0.087 | 3.964 ± 0.087 | 3.964 ± 0.087 | 3.964 ± 0.087 | 3.964 ± 0.087 | 3.964 ± 0.087 | 4,214 ± 0.087 |
The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect). Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect
| Rank across the 7 treatments | Oral Alprazolam 1 mg | Placebo | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg |
|---|---|---|---|---|---|---|---|
| Observer Rated Questionnaire 8) Maximum of Drug Strength | 2.786 ± 0.286 | 1.714 ± 0.286 | 4.571 ± 0.286 | 6.321 ± 0.286 | 3.000 ± 0.286 | 3.929 ± 0.286 | 5.679 ± 0.286 |
Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Oral Alprazolam 1 mg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Oral Alprazolam 2 mg | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Oral Alprazolam 4 mg | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Inhaled Alprazolam 0.5 mg | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Inhaled Alprazolam 1 mg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Inhaled Alprazolam 2 mg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Qualifying Session 2 mg Oral | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Qualifying Session Oral Placebo | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Event | Placebo | Oral Alprazolam 1 mg | Oral Alprazolam 2 mg | Oral Alprazolam 4 mg | Inhaled Alprazolam 0.5 mg | Inhaled Alprazolam 1 mg | Inhaled Alprazolam 2 mg | Qualifying Session 2 mg Oral | Qualifying Session Oral Placebo |
|---|---|---|---|---|---|---|---|---|---|
| SedationNervous system disorders | 0/15 | 0/15 | 0/14 | 1/15 | 0/14 | 0/15 | 0/15 | 0/28 | 0/28 |
| HypertensionVascular disorders | 0/15 | 0/15 | 0/14 | 0/15 | 0/14 | 0/15 | 0/15 | 0/28 | 1/28 |
| Age, Categorical(Participants) | Qualifying Session (Includes Crossover Group) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 31 |
| >=65 years | 0 |
| Age, Continuous(years) | Qualifying Session (Includes Crossover Group) |
|---|---|
| Mean | 38.032 ± 38.032 |
| Sex: Female, Male(Participants) | Qualifying Session (Includes Crossover Group) |
|---|---|
| Female | 9 |
| Male | 22 |
| Region of Enrollment(participants) | Qualifying Session (Includes Crossover Group) |
|---|---|
| United States | 31 |
Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com
The record gives a start of Jan 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 11 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alprazolam
Nova Pneuma Inc.